Key facts
- This treatment outlasts most postings. It is measured in years, and continuity across a move is a real risk to it.
- Two families, two mechanisms. Tamoxifen blocks the receptor; the aromatase inhibitors reduce the supply of oestrogen. Which is used depends substantially on menopausal status.
- Joint pain is the commonest reason people stop, it is a recognised class effect, and it is not imagined.
- Switching within the family is a real option, and the one most often not asked about.
- Bone thinning is the silent second effect, monitored rather than felt. Follow-up may cover bone checks, calcium and vitamin D, exercise, fall prevention and sometimes bone treatment.
- On tamoxifen, unusual vaginal bleeding is always reported. No exceptions.
- This is the opposite of HRT. One replaces oestrogen; this removes or blocks it.
The hospital part finishes. The appointments thin out, the calendar clears, and people around you understandably treat it as over.
And you are holding a box of tablets you will take for years. Longer than this posting. Possibly longer than this country.
That is the shape of this treatment, and it is why the things that quietly end it early are worth naming.
How do the two tablet families differ?
Tamoxifen blocks oestrogen action; aromatase inhibitors reduce its production. Most breast cancers that are treated this way grow in response to oestrogen. So the treatment either stops oestrogen reaching the cancer, or reduces how much oestrogen exists.
| Family | On this site | What it does | Who it is usually for |
|---|---|---|---|
| Receptor blocker | tamoxifen | Occupies the oestrogen receptor so oestrogen cannot act on it | Often used before menopause, and sometimes after |
| Aromatase inhibitors | anastrozole, letrozole, exemestane | Reduce the body’s production of oestrogen after menopause | Generally after menopause |
That distinction is not a detail. The aromatase inhibitors work on the route the body uses to make oestrogen after the ovaries stop, which is why they are not simply interchangeable with tamoxifen and why menopausal status matters so much to the choice.
What if an aromatase inhibitor makes my joints hurt?
Joint pain is the commonest reason people stop an aromatase inhibitor, and it is very often not reported before they do.
It arrives as stiffness, most noticeably in the hands in the morning: fingers that do not close properly, wrists that need a few minutes, sometimes knees and feet. The characteristic description is not sharp pain but a sudden ageing, as though a decade arrived over a few months.
For some people it eases after the first months. If it keeps limiting daily life, tell the treating team before stopping.
Three things are worth knowing about it.
It is real and it is recognised, a class effect with a mechanism behind it rather than a coincidence or a complaint. Oestrogen is involved in tendons, joint lubrication and pain perception, so removing it has predictable consequences in places that have nothing to do with the breast.
It is not a sign the disease is progressing. That fear sits underneath a great deal of unreported symptom, and it is worth naming.
And switching within the family is a genuine option. The three aromatase inhibitors are not identical, and exemestane is chemically different from the other two. Moving between them, or in some situations to tamoxifen, is a real conversation with a real chance of improving things. It is also the option people least often think to ask about, because they assume the choice was made once and is final.
Why monitor bones when I feel fine?
Aromatase inhibitors can cause bone loss before you notice a symptom. The National Cancer Centre Singapore lists osteoporosis and higher fracture risk than with tamoxifen. Tamoxifen affects bone differently after menopause, which can matter in the treatment choice.
Which tamoxifen effects need attention?
Report unusual vaginal bleeding on tamoxifen promptly. Hot flushes and period changes can occur. New leg swelling, leg pain or breathlessness needs assessment because tamoxifen slightly raises clot risk.
Tamoxifen affects the womb lining; most causes of bleeding turn out to be minor, but the exceptions are why it must always be reported.
How do I keep treatment going through a move?
Carry the treatment record and arrange the next clinic before your supply runs low. This is where an audience that moves countries needs something the standard articles do not say.
A treatment lasting several years will, for many people here, span at least one relocation. The specific risks are worth naming: the hospital that holds your records is in another country; the brand you were established on may not exist here; a new oncologist starts without your history; and the gap while all that is arranged is a gap in treatment whose benefit depends on continuity.
Before moving, ask the current team for a summary of diagnosis, medicine and intended duration. Send it to the next clinic before tablets run low. Compare the active ingredient if the box changes; the brand-name decoder can help with that. Mention any manufacturer change and bring a list of supplements, herbs or menopausal-symptom products.
Do and don’t
Do:
- Report unusual vaginal bleeding on tamoxifen to the treating team promptly.
- Tell the team when joint pain makes an aromatase inhibitor hard to continue.
- Carry the treatment summary to a new clinic before supply runs short.
Don’t:
- Stop or skip tablets without telling the team what is making adherence hard.
- Rely on long-term anti-inflammatories for joint pain without reviewing the risks.
- Hide herbal or menopausal-symptom products from the medicine list.
Sources
- Related: prostate-cancer hormone therapy, HRT and menopause, buying generic medicines in Asia
- Oncology support, women’s health and breast cancer on this site
- National Cancer Centre Singapore, breast cancer
This article is general information, checked on 10 August 2026. It contains no doses, no schedules and no treatment protocols, and it is not a substitute for the team managing your care.
